Methods: This study was a non-randomized, retrospective chart review of adult patients who received C/T August 2016 - January 2018 for any indication, including off-label, in the outpatient setting as a continuous infusion. Primary outcome evaluated was symptom resolution at the end of therapy documented in outpatient records. Secondary outcomes were microbiologic resolution at the end of therapy, if available, and patient satisfaction via a modified patient satisfaction survey assessed from follow-up phone call to patient.
Results: Seven patients received C/T in the outpatient setting and were included in the study. Infections treated varied and included pneumonia (3), cUTI (2), skin and soft tissue (1), and bacteremia (1). Most patients received 4.5gm (with 1 receiving 9gm) C/T over 24 hours mixed with normal saline via an ambulatory infusion pump refilled each day at an outpatient infusion center. All 7 patients were infected with P. aeruginosa (4 being MDR) with 1 patient co-infected with E. coli. Susceptibility testing was performed on 3 P. aeruginosa isolates (2 susceptible and 1 intermediate). Six of 7 patients reported symptom resolution at the end of therapy. Three patients were microbiologically evaluable at the end of therapy and all 3 demonstrated microbiologic resolution. Three of 7 patients completed the satisfaction survey with all 3 reporting overall satisfaction. No adverse events were documented from any patients.
Conclusion: Ceftolozane/tazobactam administered as a continuous infusion in the outpatient setting is a safe, effective, and convenient way to treat complicated P. aeruginosa infections.
B. M. Jones,
M. Wynn, None
H. N. Young, None
C. Bland, Merck: Grant Investigator and Speaker's Bureau , Grant recipient and Speaker honorarium .
See more of: Poster Abstract Session